Sleep research article
The effects of nicotine on Parkinson's disease: A systematic review and meta-analysis of experimental evidence.
Authors: Bereda G , Ahamad J
One-line summary
A sleep science research article on The effects of nicotine on Parkinson's disease: A systematic review and meta-analysis of experimental evidence..
Sleep health notes
Sleep health notes will be added by the Sleepatch editorial team.
中文解读
中文解读待补充：本站会优先为失眠研究、睡眠质量改善、昼夜节律等高价值睡眠研究添加中文说明。
Original abstract
<h4>Background and aims</h4>The relationship between nicotine exposure and Parkinson's disease (PD) remains controversial. Experimental studies, particularly preclinical trials in animal models, suggest that nicotine may exert neuroprotective effects. However, these findings have not been adequately validated in randomized controlled trials (RCTs) involving humans. This systematic review and meta-analysis aimed to evaluate experimental evidence on whether nicotine exposure exerts neuroprotective or neurodegenerative effects in PD.<h4>Methods</h4>Comprehensive searches of PubMed, Web of Science, Scopus, and Google Scholar identified 1363 studies, of which 13 met the inclusion criteria. Random-effects meta-analysis was conducted using RevMan 5.4 and R 4.1.1. Heterogeneity was assessed using the I² statistic, publication bias using funnel plots and Egger's test, and study quality using SYRCLE and ToxRTool criteria. The review followed PRISMA guidelines and was registered in PROSPERO (CRD420250633808).<h4>Results</h4>The findings of our study showed that nicotine significantly reduced apoptosis (RR, 0.49; 95 % CI, 0.34-0.71), oxidative stress (RR, 0.55; 95 % CI, 0.41-0.73), and neuroinflammation (RR, 0.62; 95 % CI, 0.49-0.79), while enhancing dopaminergic neuron survival (RR, 1.67; 95 % CI, 1.35-2.06), and mitochondrial function (RR, 1.55; 95 % CI, 1.12-2.14). The only human randomized trial showed no clinical benefit (RR, 1.00; 95 % CI, 0.84-1.49). Subgroup and meta-regression analyses identified study design, dose, duration, and model type as sources of heterogeneity.<h4>Conclusion</h4>Experimental evidence suggested that nicotine exposure confers neuroprotection against PD; however, clinical efficacy remains unproven. These findings highlighted the need for well-designed RCTs to confirm if preclinical neuroprotective effects translate into clinical benefits in humans.
Links and sources
This content is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Sleep disorders, chronic insomnia, sleep apnea, and other conditions must be evaluated and treated by a qualified healthcare professional. If you experience persistent or severe sleep problems, consult a licensed physician or sleep specialist. Research cited refers to peer-reviewed studies; individual results may vary. Sleepatch does not endorse any specific medication, supplement, or therapy.
Want a personalized sleep improvement plan?
Sleepatch can prepare a customized sleep wellness program, insomnia relief guide, and evidence-based sleep coaching based on your needs.
Explore sleep services
Comments